Form 4 for FATE FATE THERAPEUTICS INC
Accepted 2026-01-16 00:00:00 ET · period of report 2026-01-15 · accession 0001193125-26-015323 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-16 | 2026-01-15 | FATE | Adawi Kamal | CFO | A - Grant | $0.00 | +25.0K | 100.0K | +33% | $0 |
| D | 2026-01-16 | 2026-01-15 | FATE | Adawi Kamal | CFO | A - Grant | $0.00 | +75.0K | 75.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-15 | A | A | 25,000 | $0.00 | 100,000 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2026-01-15 | A | A | 75,000 | $0.00 | 75,000 | D | $1.05 · — to 2036-01-14 | 75,000 Common Stock | (F2) The shares subject to this option shall vest in 36 equal monthly installments following January 1, 2026, such that all of the shares shall be fully vested and exercisable on January 1, 2029, subject to the Reporting Person's continued service with the Issuer as of each such vesting date. |